Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC.

Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC.
复制标题

DOI:
10.3724/abbs.2021023
复制
发表时间:
2022-01-25
影响因子:
3.7
通讯作者:
Zhu Y
Zhu Y
中科院分区:
生物学3区
文献类型:
--
作者:
Yang H;Zhao H;Ren Z;Yi X;Zhang Q;Yang Z;Kuang Y;Zhu Y

文献摘要

参考文献

相似文献

肾透明细胞癌(CcRCC)的组织学特征是胞浆内脂质沉积。脂代谢紊乱在很大程度上增加了ccRCC的风险。本研究旨在探讨肉碱棕榈酰转移酶1A(CPT1A)在肾小管上皮细胞癌中的生物学功能及其分子机制。我们的结果表明,与正常肾组织相比,肾细胞癌临床标本和细胞系中CPT1a的表达均降低。用慢病毒高表达CPT1a研究了ccRCC的肿瘤表型,结果表明,体内和体外的脂质堆积和肿瘤生长都受到了抑制。此外,CPT1a通过调节B类清道夫受体1型(SRB1)和分化簇36(CD36),增加过氧化物酶体增殖物激活受体α(PPARα)的水平,从而防止胆固醇摄取和脂质积累。此外,PI3K/Akt信号通路可促进肾细胞癌中肿瘤细胞的增殖,这与CD36表达增强有关。从功能上讲,CPT1A的表达减弱对于促进肾细胞癌发生的脂质积累至关重要。总之,我们的研究揭示了CPT1a通过PPARα/CD36轴在脂质代谢中的新功能,为肾细胞癌的发病机制提供了新的理论解释。靶向CPT1a可能是治疗肾细胞癌的一种潜在的治疗策略。
Clear cell renal carcinoma (ccRCC) is histologically defined by its cytoplasmic lipid deposits. Lipid metabolism disorder largely increases the risk of ccRCC. In this study, we aimed to investigate the biological functions and molecular mechanisms of carnitine palmitoyl transferase 1A (CPT1A) in ccRCC. Our results showed that CPT1A is decreased in ccRCC clinical samples and cell lines compared with that in normal samples. Lentivirus overexpressing CPT1A was used to investigate the neoplastic phenotypes of ccRCC, and the results showed that lipid accumulation and tumor growth are attenuated both in vitro and in vivo. In addition, CPT1A prevents cholesterol uptake and lipid accumulation by increasing the peroxisome proliferator-activated receptor α (PPARα) level through regulation of Class B scavenger receptor type 1 (SRB1) and cluster of differentiation 36 (CD36). Furthermore, PI3K/Akt signaling pathway promotes tumor cell proliferation in ccRCC, which is related to the enhanced expression of CD36. Functionally, weakened CPT1A expression is critical for lipid accumulation to promote ccRCC development. Collectively, our research unveiled a novel function of CPT1A in lipid metabolism via PPARα/CD36 axis, which provides a new theoretical explanation for the pathogenesis of ccRCC. Targeting CPT1A may be a potential therapeutic strategy to treat ccRCC.
DOI: 10.1186/s40170-016-0163-7
发表时间: 2017
影响因子: 5.9
作者:
Balaban S;Shearer RF;Lee LS;van Geldermalsen M;Schreuder M;Shtein HC;Cairns R;Thomas KC;Fazakerley DJ;Grewal T;Holst J;Saunders DN;Hoy AJ
通讯作者: Hoy AJ
HSC 衍生的 COMP 通过激活 MEK/ERK 和 PI3K/AKT 信号通路驱动肝细胞癌进展。
DOI: 10.1186/s13046-018-0908-y
发表时间: 2018-09-19
期刊: Journal of experimental & clinical cancer research : CR
影响因子: --
作者:
Li Q;Wang C;Wang Y;Sun L;Liu Z;Wang L;Song T;Yao Y;Liu Q;Tu K
通讯作者: Tu K
DOI: 10.18632/oncotarget.23056
发表时间: 2017-12-26
期刊: Oncotarget
影响因子: --
作者:
Bianchi C;Meregalli C;Bombelli S;Di Stefano V;Salerno F;Torsello B;De Marco S;Bovo G;Cifola I;Mangano E;Battaglia C;Strada G;Lucarelli G;Weiss RH;Perego RA
通讯作者: Perego RA
DOI: 10.1038/ncb3124
发表时间: 2015-04
影响因子: 21.3
作者:
Boroughs LK;DeBerardinis RJ
通讯作者: DeBerardinis RJ
DOI: 10.1111/cas.14011
发表时间: 2019-06-01
期刊: CANCER SCIENCE
影响因子: 5.7
作者:
Du, Qianqian;Tan, Zheqiong;Cao, Ya
通讯作者: Cao, Ya